EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals is a small-cap biotech focused on ophthalmology whose DURAVYU product just delivered the LUGANO Phase 3 wet AMD topline — the readout that reset the whole equity story. Shares are down heavily over twelve months but the M&A conversation on the equity has now started for real.

• The base P&L is early-commercial with only trace revenue: quarterly revenue ran $966k / $620k / $696k / $507k, quarterly EPS around $-0.81 to $-1.09 — analysts model just $1.7M in FY26 revenue and $-3.72 EPS, so the equity is still binary on either the label expansion or a take-out.
• The LUGANO catalyst is now behind the tape and materially in the equity price: bulls point to peak sales and market share almost certainly higher post-readout given bidders reduced from two to one, which is the setup for a higher acquisition price and clean thesis; bears point to multiple securities-fraud class-action investigations that keep clipping any bounce.
• The corporate signal is bidirectional: unusual option volume in both directions and the class-action risk are what have kept the equity contested — meaning any specific M&A term sheet or FDA label decision is what moves the tape, not the current base-P&L.

A follow-on FDA label decision on DURAVYU or an M&A term-sheet disclosure reprices the equity higher toward acquirer-price framing; a class-action settlement disclosure or a competitive Phase 3 miss in the wet-AMD space is what puts the equity closer to cash-per-share.